anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pleural Effusion 5. Young Adult 19-24 years 6. Empyema Of Pleura 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Rapid initiation of antiretroviral therapy for people living with HIV
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. HIV infection 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Community‐based antibiotic delivery for possible serious bacterial infections in neonates in low‐ and middle‐income countries
1. Neonate 2. Middle Income 3. Bacterial Infection 4. Birth to 1 mo 5. Low Income
Provide patient population that should be included in the study
Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. White Blood Cell Count Low 10. HIV infection 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Early versus delayed antiretroviral treatment in HIV‐positive people with cryptococcal meningitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Cryptococcal meningitis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. HIV infection 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Influenza vaccine for chronic obstructive pulmonary disease (COPD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Chronic Bronchitis 7. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for necrotizing soft tissue infections in adults
1. Aged 80 and over 80+ years 2. Necrotizing Soft Tissue Infection 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to increase influenza vaccination rates of those 60 years and older in the community
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Healthcare Professional 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Osmotic therapies added to antibiotics for acute bacterial meningitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Bacterial Meningitis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antidepressants for depression in adults with HIV infection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Depression 6. HIV infection 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for pneumonia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Pneumonia 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to increase tuberculosis case detection at primary healthcare or community‐level services
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Routine antibiotic prophylaxis after normal vaginal birth for reducing maternal infectious morbidity
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Normal Delivery 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute Respiratory Tract Infection 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Short‐course versus long‐course intravenous therapy with the same antibiotic for severe community‐acquired pneumonia in children aged two months to 59 months
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Community Acquired Pneumonia
Provide patient population that should be included in the study
Intravenous immunoglobulin for the treatment of childhood encephalitis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Encephalitis 4. Infant 1 to 23 mo 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Probiotics for preventing urinary tract infection in people with neuropathic bladder
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Neurogenic Bladder
Provide patient population that should be included in the study
Isoniazid for preventing tuberculosis in HIV‐infected children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. HIV infection
Provide patient population that should be included in the study
Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
1. Infant 1 to 23 mo 2. Persistent Cough 3. Birth to 1 mo 4. Wheezing 5. Bronchiolitis
Provide patient population that should be included in the study
Zinc supplementation for the treatment of measles in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Measles 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Acute Exacerbation Of Chronic Obstructive Airways Disease 4. Young Adult 19-24 years 5. Acute Exacerbation Of Chronic Bronchitis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for acute bronchitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Acute Bronchitis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Pre‐admission antibiotics for suspected cases of meningococcal disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Meningococcal Meningitis 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Staphylococcus Carrier 8. Surgery 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical versus non‐surgical management for pleural empyema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Pleural Effusion 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Empyema Of Pleura 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
1. Sepsis-associated Organ Dysfunction 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Sepsis 6. Septic Shock 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Dressings for the prevention of surgical site infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Surgery 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiviral agents for infectious mononucleosis (glandular fever)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Infectious Mononucleosis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates
1. Neonate 2. Birth to 1 mo 3. Sepsis
Provide patient population that should be included in the study
School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents
1. Child 6-12 years 2. Young Adult 19-24 years 3. Healthy 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Primary wound healing 6. Middle Aged 45-64 years 7. Surgical Wound 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluid therapy for acute bacterial meningitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Bacterial Meningitis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for ventilator‐associated pneumonia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Ventilator Associated Pneumonia 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
HIV prevention advice for people with serious mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Severe mental disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for men and women with their first episode of genital herpes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Genital Herpes Simplex 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Exercise prior to influenza vaccination for limiting influenza incidence and its related complications in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Behavioral interventions for improving contraceptive use among women living with HIV
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. HIV infection 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for treating nerve damage in leprosy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Type 1 Lepra Reaction 6. Leprosy 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Secondary Peripheral Neuropathy 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Viral Encephalitis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pulmonary Tuberculosis 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic antifungal therapy for tinea capitis in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Tinea Capitis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for managing tuberculous meningitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Meningitis tuberculous 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early removal versus expectant management of central venous catheters in neonates with bloodstream infection
1. Neonate 2. Septicemia 3. Birth to 1 mo 4. Central Venous Catheterisation 5. Preterm Infant
Provide patient population that should be included in the study
Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Urinary Tract Infection 5. Cystitis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antihelminthics in helminth‐endemic areas: effects on HIV disease progression
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Helminth Infection 8. Young Adult 19-24 years 9. HIV infection 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Antibiotics for preventing suppurative complications from undifferentiated acute respiratory infections in children under five years of age
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Acute Respiratory Infections 4. Undifferentiated Illness 5. Cough
Provide patient population that should be included in the study
Antithrombin III for critically ill patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Aged 65-79 years
Provide patient population that should be included in the study
Frequency of dressing changes for central venous access devices on catheter‐related infections
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Peripherally Inserted Central Venous Access Patent 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Central Venous Catheterisation 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Infection By Strongyloides Stercoralis 10. Chronic Infectious Disease 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Critical Illness 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Semi‐recumbent position versus supine position for the prevention of ventilator‐associated pneumonia in adults requiring mechanical ventilation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Mechanical ventilation 5. Endotracheal intubation 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Linezolid versus vancomycin for skin and soft tissue infections
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ski infection 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Soft Tissue Infection 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjuvant corticosteroids for reducing death in neonatal bacterial meningitis
1. Bacterial Meningitis 2. Neonate 3. Birth to 1 mo
Provide patient population that should be included in the study
Duration of treatment for asymptomatic bacteriuria during pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Asymptomatic Bacteriuria In Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Steroids for symptom control in infectious mononucleosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Infectious Mononucleosis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo 4. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants
1. Very Preterm Infant (28-31 weeks) 2. Birth to 1 mo 3. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Prenatal education for congenital toxoplasmosis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for preventing lower respiratory tract infections in high‐risk children aged 12 years and under
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. At Risk For Infection
Provide patient population that should be included in the study
Heliox inhalation therapy for bronchiolitis in infants
1. Acute Bronchiolitis 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
Corticosteroids for acute bacterial meningitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Bacterial Meningitis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta2‐agonists for acute cough or a clinical diagnosis of acute bronchitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Acute Cough 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Acute Bronchitis 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Incentives and enablers to improve adherence in tuberculosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Tuberculosis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Short‐course versus prolonged‐course antibiotic therapy for hospital‐acquired pneumonia in critically ill adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Nosocomial Pneumonia 4. Young Adult 19-24 years 5. Critical Illness 6. Intensive Care 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Surfactant therapy for bronchiolitis in critically ill infants
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Critical Illness 4. Birth to 1 mo 5. Intensive Care 6. Mechanical ventilation 7. Bronchiolitis
Provide patient population that should be included in the study
Silver‐coated endotracheal tubes for prevention of ventilator‐associated pneumonia in critically ill patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Intubation 7. Mechanical ventilation 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for prevention of herpes simplex labialis (cold sores on the lips)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Recurrent Herpes Simplex Labialis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for preventing recurrent urinary tract infection during pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Urinary Tract Infection 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for women for preventing neonatal tetanus
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Second Trimester Pregnancy 4. Young Adult 19-24 years 5. Pregnancy 6. Third Trimester Pregnancy 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. General Health Good 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic lock for the prevention of catheter‐related infection in neonates
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Central Venous Catheterisation 4. Preterm Infant
Provide patient population that should be included in the study
Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Fracture Of Base Of Skull 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Multiple chronic conditions 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Pneumocystis jirovecii pneumonia 11. Young Adult 19-24 years 12. Birth to 1 mo 13. HIV infection
Provide patient population that should be included in the study
Leukotriene inhibitors for bronchiolitis in infants and young children
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Bronchiolitis
Provide patient population that should be included in the study
Azithromycin for acute lower respiratory tract infections
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Acute Lower Respiratory Tract Infection 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Chlorhexidine skin or cord care for prevention of mortality and infections in neonates
1. Neonate 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Parenteral nutrition 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for parasitic eosinophilic meningitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Eosinophilic Meningitis 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Acute Pyelonephritis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Skin preparation with alcohol versus alcohol followed by any antiseptic for preventing bacteraemia or contamination of blood for transfusion
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Venipuncture 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Low dose versus high dose stavudine for treating people with HIV infection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. HIV infection 6. Aged 65-79 years
Provide patient population that should be included in the study
Macrolides for diffuse panbronchiolitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Diffuse Panbronchiolitis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pneumococcal vaccination during pregnancy for preventing infant infection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjunctive hyperbaric oxygen for necrotizing fasciitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Necrotizing Fasciitis 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for community‐acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Lower Respiratory Tract Infection 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Infection Due To Mycoplasma Pneumoniae 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic regimens for management of intra‐amniotic infection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Intra-amniotic Infection Of Fetus 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Surfactant for meconium aspiration syndrome in term and late preterm infants
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Late Preterm Infant (34-36 weeks) 4. Meconium Aspiration Syndrome
Provide patient population that should be included in the study
Vaginal chlorhexidine during labour to prevent early‐onset neonatal group B streptococcal infection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Group B Streptococcus Carrier 5. Maternal And/or Fetal Condition Affecting Labor And/or Delivery 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery
1. Adult 19-44 years 2. Cesarean Section 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Amantadine and rimantadine for influenza A in children and the elderly
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Influenza Due To Influenza A Virus
Provide patient population that should be included in the study
Antibiotics for meconium‐stained amniotic fluid in labour for preventing maternal and neonatal infections
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Meconium In Amniotic Fluid 6. Normal Labor 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator‐associated pneumonia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Ventilator Associated Pneumonia 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Strategies of testing for syphilis during pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for community‐acquired pneumonia in adult outpatients
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Community Acquired Pneumonia 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for bronchiolitis in children under two years of age
1. Infant 1 to 23 mo 2. Birth to 1 mo 3. Bronchiolitis
Provide patient population that should be included in the study
Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Organ Transplant 5. Infant 1 to 23 mo 6. Corticosterone 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Immunosuppression 11. Middle Aged 45-64 years 12. Primary Immune Deficiency Disorder 13. Young Adult 19-24 years 14. Malnutrition 15. Birth to 1 mo 16. Bone Marrow 17. Cancer
Provide patient population that should be included in the study
Acellular vaccines for preventing whooping cough in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Healthy
Provide patient population that should be included in the study
Topical antifungal treatments for tinea cruris and tinea corporis
1. Aged 80 and over 80+ years 2. Tinea Cruris 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Tinea Corporis 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV and other sexually transmitted infections
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Sexually Transmitted Infection 6. HIV infection 7. Current Drug User 8. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics for acute pyelonephritis in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Acute Pyelonephritis 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. HIV infection 6. Aged 65-79 years
Provide patient population that should be included in the study
Corticosteroids for dengue infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Dengue fever 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for post‐exposure prophylaxis against varicella (chickenpox) in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Exposure To Varicella 9. Birth to 1 mo 10. Aged 65-79 years 11. Healthy 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Bronchodilators for bronchiolitis
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Bronchiolitis
Provide patient population that should be included in the study
Intrapartum antibiotics for known maternal Group B streptococcal colonization
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years 6. Streptococcal Colonization
Provide patient population that should be included in the study
Hormonal contraception for women exposed to HIV infection
1. Healthy
Provide patient population that should be included in the study
Post‐exposure passive immunisation for preventing measles
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Exposure To Rubeola Virus 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Healthy 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic corticosteroids for acute sinusitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Acute Sinusitis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Over‐the‐counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Pneumonia 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Cough 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Intermittent versus daily therapy for treating tuberculosis in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Tuberculosis 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Sepsis 9. Hospitalization 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intranasal steroids for acute sinusitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acute Sinusitis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Infection control strategies for preventing the transmission of meticillin‐resistant Staphylococcus aureus (MRSA) in nursing homes for older people
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Healthcare Professional 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Living In Nursing Home
Provide patient population that should be included in the study
Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) in non surgical wounds
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Wound 6. Aged 65-79 years 7. Methicillin Resistant Staphylococcus Aureus Infection
Provide patient population that should be included in the study
Continuous negative extrathoracic pressure or continuous positive airway pressure compared to conventional ventilation for acute hypoxaemic respiratory failure in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Hypoxemic Respiratory Failure 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined and alternating paracetamol and ibuprofen therapy for febrile children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Fever 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for preventing meningococcal infections
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Healthy
Provide patient population that should be included in the study
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Bacterial Sepsis 5. Infant 1 to 23 mo 6. Septic Shock 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Sepsis-associated Organ Dysfunction 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Optimal timing for intravascular administration set replacement
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Hospitalization 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Arterial catheterization 11. Young Adult 19-24 years 12. Central Venous Catheter In Situ 13. Birth to 1 mo 14. Peripherally Inserted Central Venous Catheter In Situ
Provide patient population that should be included in the study
Antibiotics for preventing complications in children with measles
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Measles 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Glucocorticoids for acute viral bronchiolitis in infants and young children
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Acute Viral Bronchiolitis 4. Birth to 1 mo
Provide patient population that should be included in the study
Antibiotics for community‐acquired pneumonia in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Community Acquired Pneumonia 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years 6. At Risk For Infection
Provide patient population that should be included in the study
De‐escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock
1. Sepsis-associated Organ Dysfunction 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Sepsis 6. Septic Shock 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acquired Immunodeficiency Syndrome 5. Young Adult 19-24 years 6. HIV infection 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for preventing influenza in people with asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Extracorporeal membrane oxygenation for critically ill adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cardiac Failure 5. Young Adult 19-24 years 6. Respiratory Failure 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Mental Health First Aid as a tool for improving mental health and well‐being
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Mental disorder 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Kidney Stone 6. Aged 65-79 years
Provide patient population that should be included in the study
Magnetic seizure therapy for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Carnitine supplements for people with chronic kidney disease requiring dialysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Chronic Kidney Disease 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Renal Dialysis
Provide patient population that should be included in the study
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Chronic Kidney Disease 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Catatonia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive behavioural therapy (group) for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Negative pressure wound therapy for managing the open abdomen in non‐trauma patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Open abdomen 6. Aged 65-79 years
Provide patient population that should be included in the study
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Self‐management interventions for people with chronic obstructive pulmonary disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Chronic Obstructive Pulmonary Disease 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Obstructive Pulmonary Disease
Provide patient population that should be included in the study
Preoperative hair removal to reduce surgical site infection
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Surgery 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Exercise training for adult lung transplant recipients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Transplant Of Lung 6. Transplant recipient 7. Aged 65-79 years
Provide patient population that should be included in the study
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Obstructive Pulmonary Disease 6. Aged 65-79 years